Etanercept: an overview of its role in the treatment of psoriasis

Author: Galindo Malini Patel   Bartlett Brenda L   Gewirtzman Aron   Mendoza Natalia   Tremaine Anne Marie   Tyring Stephen K  

Publisher: Informa Healthcare

ISSN: 1742-5255

Source: Expert Opinion on Drug Metabolism and Toxicology, Vol.4, Iss.3, 2008-03, pp. : 305-310

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Psoriasis is a chronic and disabling disease affecting patients' quality of life. Objectives: Over the past decade, there has been significant growth in the knowledge of the proinflammatory pathways involved in psoriasis, including the role of increased levels of TNF. This knowledge has led to the increased use of biologic therapy, with such drugs as etanercept, a soluble TNF receptor fusion protein, aimed at inhibiting the actions of TNF. The goal of biologic generation is to provide selectively targeted therapy with fewer adverse events than traditional therapies. Methods: Etanercept has been studied extensively and Phase III studies have been completed. Conclusion: Clinical data reviewed for etanercept-treated moderate to severe psoriasis have shown good efficacy, tolerability and a low adverse event profile.